CSF amyloid 38 as a novel diagnostic marker for dementia with Lewy bodies
Open accessAbstract
BACKGROUND: The clinical distinction between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) is sometimes difficult, particularly in mild cases. Although CSF markers such as amyloid β42 (Aβ42) and P-tau can distinguish between AD and normal controls, their ability to distinguish between AD and DLB is not adequate. OBJECTIVE: This study aims to investigate whether CSF markers, in particular levels of Aβ38, can differentiate between mild AD and DLB. METHODS: 85 individuals were included after standardised diagnostic procedures: 30 diagnosed as probable AD, 23 probable DLB, 20 probable Parkinson's disease dementia and 12 non-demented control subjects. CSF levels of Aβ38, Aβ40 and Aβ42 were determined using commercially available ultra-sensitive multi-array kit assay (MSD) for human Aβ peptides. Total tau (T-tau) and phosphorylated tau (P-tau) were analysed using ELISA (Innotest). In addition, combinations (Aβ42/Aβ38, Aβ42/Aβ40, Aβ42/P-tau and Aβ42/Aβ38/P-tau) were assessed. RESULTS: Significant between group differences were found for all CSF measures, and all except Aβ40, Aβ42 and Aβ42/P-tau differed between AD and DLB. The Aβ42/Aβ38 ratio was the measure that best discriminated between AD and DLB (AUC 0.765; p<0.005), with a sensitivity of 78% and a specificity of 67%. CONCLUSION: This study suggests that the level of Aβ38 can potentially contribute in the diagnostic distinction between AD and DLB when combined with Aβ42. Single measures had low diagnostic accuracy, suggesting that developing a panel of markers is the most promising strategy. Studies with independent and larger samples and a priori cut-offs are needed to test this hypothesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CSF levels of Aβ38, Aβ42, and the Aβ42/Aβ38 ratio can distinguish AD from other dementias.
“In addition, it has been shown that the levels of Aβ38, Aβ42 and the Aβ42/Aβ38 ratio in cerebral spinal fluid (CSF) can be used to distinguish AD from other dementias [32–34].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882 · see citing works
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · see citing works
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
Self-citationResearch criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P., Irwig, L., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Clinical Biochemistry · doi:10.1016/s0009-9120(02)00443-5 · Cited by 3,182 · see citing works
Unified Parkinson's Disease Rating Scale
(2012) · Springer eBooks · doi:10.1007/springerreference_184495 · Cited by 3,071 · see citing works
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · see citing works
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789 · see citing works
Self-citationConsensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works
Dementia associated with Parkinson's disease
Emre, M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00351-x · Cited by 686 · see citing works
DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256715.13907.d3 · Cited by 548 · see citing works
Self-citationAarsland, D., Ballard, C. G., Walker, Z., Boström, F., Alves, G. W., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70146-2 · Cited by 464 · see citing works
Self-citationFerman, T. J., Smith, G. E., Boeve, B. F., Ivnik, R. J., Petersen, R. C., Knopman, D. S., Graff‐Radford, N. R., Parisi, J. E., & Dickson, D. W. (2004) · Neurology · doi:10.1212/wnl.62.2.181 · Cited by 463 · see citing works
Unified Parkinson’s Disease Rating Scale
Fish, J. E. (2018) · Springer eBooks · doi:10.1007/978-3-319-57111-9_1836 · Cited by 406 · see citing works
Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia
Walker, M. P., Ayre, G., Cummings, J. L., Wesnes, K. A., McKeith, I. G., O'Brien, J. T., & Ballard, C. G. (2000) · Neurology · doi:10.1212/wnl.54.8.1616 · Cited by 270 · see citing works
Self-citationWhat best differentiates Lewy body from Alzheimer's disease in early-stage dementia?
Tiraboschi, P., Salmon, D. P., Hansen, L. A., Hofstetter, R., Thal, L. J., & Corey‐Bloom, J. (2006) · Brain · doi:10.1093/brain/awh725 · Cited by 270 · see citing works
CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease
Blennow, K., Vanmechelen, E., & Hampel, H. J. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 263 · see citing works
Self-citationFluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker
Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260 · see citing works
Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease
Williams, M. M., Xiong, C., Morris, J. C., & Galvin, J. E. (2006) · Neurology · doi:10.1212/01.wnl.0000247041.63081.98 · Cited by 239 · see citing works
Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias
Aarsland, D., Perry, R., Larsen, J. O., McKeith, I. G., O'Brien, J. T., Perry, E. K., Burn, D. J., & Ballard, C. G. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0514 · Cited by 222 · see citing works
Self-citationBibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H., Sparbier, K., Av, S., Cepek, L., Trenkwalder, C., Rüther, E., et al. (2006) · Brain · doi:10.1093/brain/awl063 · Cited by 209 · see citing works
Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria
Aarsland, D., Rongve, A., Nore, S. P., Skogseth, R. E., Skulstad, S., Ehrt, U., Hoprekstad, D., & Ballard, C. G. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000165917 · Cited by 207 · see citing works
Self-citationm, F. B., Jönsson, L., Minthon, L., & Londos, E. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318065c4a9 · Cited by 172 · see citing works
Self-citationVanderstichele, H., de Vreese, K., Blennow, K., Andreasen, N., Sindic, C. J. M., Ivanoiu, A., Hampel, H. J., Bürger, K., Parnetti, L., Lanari, A., et al. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.258 · Cited by 170 · see citing works
Self-citationFujishiro, H., Ferman, T. J., Boeve, B. F., Smith, G. E., Graff‐Radford, N. R., Uitti, R. J., Wszołek, Z. K., Knopman, D. S., Petersen, R. C., Parisi, J. E., et al. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31817d7a1d · Cited by 161 · see citing works
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152 · see citing works
Koopman, K., Bastard, N. L., Martin, J., Nagels, G., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.02.017 · Cited by 151 · see citing works
CSF biomarkers for mild cognitive impairment
Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
Bonanni, L., Thomas, A., & ONOFRJ, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000224698.67660.45 · Cited by 125 · see citing works
Patients with Lewy body dementia use more resources than those with Alzheimer's disease
Boström, F., Jönsson, L., Minthon, L., & Londos, E. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1738 · Cited by 115 · see citing works
Self-citationIn dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution
Weisman, D., Cho, M., Taylor, C., Adame, A., Thal, L. J., & Hansen, L. A. (2007) · Neurology · doi:10.1212/01.wnl.0000266626.64913.0f · Cited by 100 · see citing works
Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias
Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H., Wolf, S., Trenkwalder, C., Otto, M., Stiens, G., Rüther, E., Kornhuber, J., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001967 · Cited by 90 · see citing works
Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity
Aarsland, D., Londos, E., & Ballard, C. G. (2009) · International Psychogeriatrics · doi:10.1017/s1041610208008612 · Cited by 72 · see citing works
Self-citationEarly Discriminatory Diagnosis of Dementia with Lewy Bodies
Aarsland, D., Kurz, M. W., Beyer, M. K., Brønnick, K., Nore, S. P., & Ballard, C. G. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000113417 · Cited by 44 · see citing works
Self-citationPathological substrate of dementia in Parkinson's disease—its relation to DLB and DLBD
Mori, H. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.02.012 · Cited by 24 · see citing works
Ballard, C. G., Jones, E. L., Londos, E., Minthon, L., Francis, P. T., & Aarsland, D. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209991049 · Cited by 21 · see citing works
Self-citationPathological substrate of dementia in Parkinson's disease—Its relation to DLB and DLBD
Jellinger, K. A. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.09.001 · Cited by 19 · see citing works
IN DEMENTIA WITH LEWY BODIES, BRAAK STAGE DETERMINES PHENOTYPE, NOT LEWY BODY DISTRIBUTION
Dickson, D. W., & Fujishiro, H. (2008) · Neurology · doi:10.1212/01.wnl.0000315887.53460.29 · Cited by 4 · see citing works
O1‐02‐01: Risk of nursing home placement in dementia with Lewy bodies and Alzheimer's dementia
Rongve, A., Skogseth, R. E., & Aarsland, D. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.196 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [5]5. Rongve A, Skogseth R, Aarsland D. Risk of nursing home placement in Dementia with Lewy Bodies. ICAD 2009; 2009; Vienna, Austria: The Journal of The Alzheimer's Association; 2009.
Cited by
Sorted by citations
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · see citing works
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
Self-citationJanelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456 · see citing works
Self-citationTang, W., Huang, Q., Wang, Y., Wang, Z.-Y., & Yao, Y.-Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.07.015 · Cited by 38 · see citing works
- Authors
- Mulugeta, E., Londos, E., Ballard, C., Alves, G., Zetterberg, H., Blennow, K., Skogseth, R., Minthon, L., & Aarsland, D.
- Affiliations
- King's College London (GB)
- Lund University (SE)
- Stavanger University Hospital (NO)
- University of Gothenburg (SE)
- University of Bergen (NO)
- Corresponding author
- Aarsland, D.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2010-11-03
- Volume
- 82
- Issue
- 2
- Pages
- 160-164
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2103187247
- Cited by
- 54
- References
- 43
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 7 · 2012: 5
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dementia with Lewy bodies, Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, Aβ40, phosphorylated tau, total tau, differential diagnosis, Parkinson's disease dementia, biomarker panel
- MeSH terms
- Aged, Alzheimer Disease, Diagnosis, Differential, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Neuropsychological Tests, Norway, Parkinson Disease, Peptide Fragments, ROC Curve, Sex Characteristics, Sweden, Reproducibility of Results, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
